| Neuro Synchrony Llc | |
|
1745 E Hwy 50 Ste B1 Clermont FL 34711-5190 | |
| (407) 519-0466 | |
| (833) 405-0495 |
| Full Name | Neuro Synchrony Llc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 1745 E Hwy 50 Ste B1, Clermont, Florida |
| Authorized Official Name and Position | Firas Sioufi (OWNER) |
| Authorized Official Contact | 4075190466 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Neuro Synchrony Llc 9622 Lake Hugh Dr Gotha FL 34734-4600 Ph: (407) 519-0466 | Neuro Synchrony Llc 1745 E Hwy 50 Ste B1 Clermont FL 34711-5190 Ph: (407) 519-0466 |
| NPI Number | 1104458462 |
|---|---|
| Provider Enumeration Date | 02/05/2020 |
| Last Update Date | 02/05/2020 |
| Certification Date | 02/05/2020 |
| Medicare PECOS PAC ID | 1153752373 |
|---|---|
| Medicare Enrollment ID | O20200504000108 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104458462 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | (* (Not Available)) | Primary |
| Provider Name | M Firas Sioufi |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1427091727 PECOS PAC ID: 1759386873 Enrollment ID: I20090610000018 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
| Provider Name | Usman Tanveer Malik |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457520561 PECOS PAC ID: 1951426782 Enrollment ID: I20100916000313 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
| Provider Name | Shannon Rose Weber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659766244 PECOS PAC ID: 3779802160 Enrollment ID: I20150506002273 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
| Provider Name | Scott D Doll |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033685847 PECOS PAC ID: 2466798004 Enrollment ID: I20190117003777 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
| Provider Name | Shermaine C Acosta |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093478828 PECOS PAC ID: 7719377407 Enrollment ID: I20211213001711 |
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
News Archive
Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.
Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as "Wuhan pneumonia" (coronavirus 2019-nCoV).
› Verified 3 days ago
Epic Behavioral Solutions Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1060 W Highway 50 Ste 212, Clermont, FL 34711 Phone: 352-325-3603 | |
Pathways To Revelation, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1064 W Highway 50 Ste 219, Clermont, FL 34711 Phone: 407-588-7466 | |
Mind Works Psychotherapy, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 221 N Highway 27 Unit F, Clermont, FL 34711 Phone: 352-243-5901 Fax: 352-243-4187 | |
Comprehensive Counseling And Therapy ,llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 704 E. Grand Hwy, Clermont, FL 34711 Phone: 352-346-0753 Fax: 352-708-5311 | |
Family Life Counseling Center Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1230 Oakley Seaver Dr Ste 307, Clermont, FL 34711 Phone: 352-988-6673 Fax: 352-363-2496 | |
Pamela Segura Mental Health Counseling Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 792 E Montrose St, Clermont, FL 34711 Phone: 407-914-8373 Fax: 352-646-7144 | |
Soar Centers For Behavioral Care Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2113 Ruby Red Blvd Ste A, Clermont, FL 34714 Phone: 407-427-6850 |